CFT8634, a bifunctional degradation activation compound (BiDACTM) of BRD9, was evaluated in a Phase 1/2 clinical trial (NCT05355753) for patients with locally advanced or metastatic SMARCB1-perturbed cancers, including SS and SMARCB1-null tumours. Here, SMARCB1 is linked to neoplasm.